447 related articles for article (PubMed ID: 19581216)
1. Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk.
Bozina N; Bradamante V; Lovrić M
Arh Hig Rada Toksikol; 2009 Jun; 60(2):217-42. PubMed ID: 19581216
[TBL] [Abstract][Full Text] [Related]
2. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
Zhou SF; Liu JP; Chowbay B
Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome P450: Polymorphisms and Roles in Cancer, Diabetes and Atherosclerosis.
Elfaki I; Mir R; Almutairi FM; Duhier FMA
Asian Pac J Cancer Prev; 2018 Aug; 19(8):2057-2070. PubMed ID: 30139042
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome P450 pharmacogenetics and cancer.
Rodriguez-Antona C; Ingelman-Sundberg M
Oncogene; 2006 Mar; 25(11):1679-91. PubMed ID: 16550168
[TBL] [Abstract][Full Text] [Related]
5. Markers of genetic susceptibility in human environmental hygiene and toxicology: the role of selected CYP, NAT and GST genes.
Thier R; Brüning T; Roos PH; Rihs HP; Golka K; Ko Y; Bolt HM
Int J Hyg Environ Health; 2003 Jun; 206(3):149-71. PubMed ID: 12872524
[TBL] [Abstract][Full Text] [Related]
6. Polymorphic Variants of Cytochrome P450: Relevance to Cancer and Other Diseases.
Daly AK
Adv Pharmacol; 2015; 74():85-111. PubMed ID: 26233904
[TBL] [Abstract][Full Text] [Related]
7. Cytochrome P450 gene polymorphism and cancer.
Agundez JA
Curr Drug Metab; 2004 Jun; 5(3):211-24. PubMed ID: 15180491
[TBL] [Abstract][Full Text] [Related]
8. Role of Metabolic Enzymes P450 (CYP) on Activating Procarcinogen and their Polymorphisms on the Risk of Cancers.
He X; Feng S
Curr Drug Metab; 2015; 16(10):850-63. PubMed ID: 26652254
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphism of cytochrome P450 as a biomarker of susceptibility to environmental toxicity.
Hong JY; Yang CS
Environ Health Perspect; 1997 Jun; 105 Suppl 4(Suppl 4):759-62. PubMed ID: 9255558
[TBL] [Abstract][Full Text] [Related]
10. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer.
Nebert DW; McKinnon RA; Puga A
DNA Cell Biol; 1996 Apr; 15(4):273-80. PubMed ID: 8639263
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphism and toxicology--with emphasis on cytochrome p450.
Johansson I; Ingelman-Sundberg M
Toxicol Sci; 2011 Mar; 120(1):1-13. PubMed ID: 21149643
[TBL] [Abstract][Full Text] [Related]
12. [Interindividual differences in efficacy and toxicity induced by therapeutic drugs and xenobiotics in relation to genetic polymorphisms in xenobiotic metabolizing enzymes].
Ozawa S
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 1998; (116):69-81. PubMed ID: 10097514
[TBL] [Abstract][Full Text] [Related]
13. Individuality in cytochrome P450 expression and its association with the nephrotoxic and carcinogenic effects of chemicals.
Wolf CR
IARC Sci Publ; 1991; (115):281-7. PubMed ID: 1820342
[TBL] [Abstract][Full Text] [Related]
14. Cytochrome P450 genetic polymorphisms of Mexican indigenous populations.
Sosa-Macías M; Llerena A
Drug Metabol Drug Interact; 2013; 28(4):193-208. PubMed ID: 24145057
[TBL] [Abstract][Full Text] [Related]
15. Genetic variability in susceptibility and response to toxicants.
Ingelman-Sundberg M
Toxicol Lett; 2001 Mar; 120(1-3):259-68. PubMed ID: 11323184
[TBL] [Abstract][Full Text] [Related]
16. Cytochrome P450 Structure, Function and Clinical Significance: A Review.
Manikandan P; Nagini S
Curr Drug Targets; 2018; 19(1):38-54. PubMed ID: 28124606
[TBL] [Abstract][Full Text] [Related]
17. In vitro assessment of the allelic variants of cytochrome P450.
Hiratsuka M
Drug Metab Pharmacokinet; 2012; 27(1):68-84. PubMed ID: 22041138
[TBL] [Abstract][Full Text] [Related]
18. Assessment of cancer susceptibility in humans by use of genetic polymorphisms in carcinogen metabolism.
Ikawa S; Uematsu F; Watanabe K; Kimpara T; Osada M; Hossain A; Sagami I; Kikuchi H; Watanabe M
Pharmacogenetics; 1995; 5 Spec No():S154-60. PubMed ID: 7581487
[TBL] [Abstract][Full Text] [Related]
19. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects.
Ingelman-Sundberg M; Sim SC; Gomez A; Rodriguez-Antona C
Pharmacol Ther; 2007 Dec; 116(3):496-526. PubMed ID: 18001838
[TBL] [Abstract][Full Text] [Related]
20. Cytochrome P450 in Cancer Susceptibility and Treatment.
Mittal B; Tulsyan S; Kumar S; Mittal RD; Agarwal G
Adv Clin Chem; 2015; 71():77-139. PubMed ID: 26411412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
